These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
36. [The implantable cardioverter-defibrillator: the Portuguese experience]. Adragão P; Neves J; Sousa J; Fançoni J; da Silva N; Antunes E; Elvas L; Bernardo J Rev Port Cardiol; 1997 Apr; 16(4):367-74, 351-2. PubMed ID: 9254126 [TBL] [Abstract][Full Text] [Related]
37. Factors predisposing to ventricular tachyarrhythmia leading to appropriate ICD intervention in patients with coronary artery disease or non-ischaemic dilated cardiomyopathy. Lelakowski J; Piekarz J; Rydlewska A; Majewski J; Senderek T; Ząbek A; Małecka B Kardiol Pol; 2012; 70(12):1264-75. PubMed ID: 23264245 [TBL] [Abstract][Full Text] [Related]
38. Risk stratification for implantable cardioverter defibrillator therapy: the role of the wearable cardioverter-defibrillator. Klein HU; Goldenberg I; Moss AJ Eur Heart J; 2013 Aug; 34(29):2230-42. PubMed ID: 23729691 [TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of celivarone, with amiodarone as calibrator, in patients with an implantable cardioverter-defibrillator for prevention of implantable cardioverter-defibrillator interventions or death: the ALPHEE study. Kowey PR; Crijns HJ; Aliot EM; Capucci A; Kulakowski P; Radzik D; Roy D; Connolly SJ; Hohnloser SH; Circulation; 2011 Dec; 124(24):2649-60. PubMed ID: 22082672 [TBL] [Abstract][Full Text] [Related]
40. Avoiding Untimely Implantable Cardioverter/Defibrillator Implantation by Intensified Heart Failure Therapy Optimization Supported by the Wearable Cardioverter/Defibrillator-The PROLONG Study. Duncker D; König T; Hohmann S; Bauersachs J; Veltmann C J Am Heart Assoc; 2017 Jan; 6(1):. PubMed ID: 28096098 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]